| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Medical Oncology, University Hospital Rotterdam-Daniel den Hoed Cancer Center, Josephine Nefkens Institute, 3000 DR Rotterdam [P. W. S., A. W. M. B., H. B., G. S., K. N.], and Department of Molecular Genetics, Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, 2300 RA Leiden [J. A. B., H. d. D., J. B.], the Netherlands
 |
ABSTRACT |
|---|
 Top ABSTRACT IntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
|
Introduction |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
We used the budding yeast Saccharomyces cerevisiae as a model system to study drug sensitivity and resistance (5) . In this study, we performed a genome-wide screen to identify and characterize novel cisplatin sensitivity genes, and we found that disruption of the yeast YMR216C locus corresponding to the SKY1 (SR3 protein-specific kinase from budding yeast) gene conferred cellular resistance to cisplatin. We demonstrate that down-regulation of the human Sky1p homologue SRPK1 (SR protein-specific kinase) by antisense ODNs in human ovarian carcinoma cells also confers cisplatin resistance. This is the first report in which SKY1 and SRPK1 are associated with alterations in cisplatin sensitivity, and our findings indicate that SRPK1 might potentially be of importance for studying clinical drug resistance.
|
Materials and Methods |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
35 (kindly provided by Dr. P. B. Ross-Macdonald, Yale University, New Haven, CT), by means of a high-efficiency protocol. Transformants were selected on complete YNB medium plates lacking leucine. Leucine-proficient S. cerevisiae cells were replated at a density of 104 cells/94-mm dish on selective YNB medium plates containing 4 µg/ml cisplatin [Platosin; cis-diamminedichloroplatinum(II); Pharmachemie, Haarlem, the Netherlands]. Colonies surviving this one-step drug selection were picked and retested for cisplatin resistance in semiquantitative spot assays and quantitative clonogenic survival assays as described previously (5)
. Inverse PCR (8)
was used to obtain sequences flanking the transposon elements. PCR products were purified and sequenced using transposon-specific primers (7)
. A gene-specific SKY1 disruption was generated in strain MGSC283 (an isogenic ura3-1 derivative of MGSC131) by one-step gene replacement performed as described by Rothstein (9)
, which yielded MGSC-sky1 cells. The construct used in the one-step gene replacement procedure was made using primers SKY1-5A (5'-GTA-AGA-AAG-CTG-GGA-TGG-GGC-CAC-TTC-TCA-TCT-TTG-ACA-GCT-TAT-CAT-C-3') and SKY1-3 (5'-CGG-AAC-CAC-TCC-CGT-ACA-ACT-CTC-TAT-CAG-GTA-CCC-ACT-CGT-GCA-CCC-3'). A probe hybridizing to the 0.5-kb 5' SpeI-HindIII SKY1 fragment was used to confirm successful disruption by Northern blotting. Sequences were analyzed using the Saccharomyces Genome Database. Database entries used for amino acid comparisons between Sky1p and its human counterpart, SRPK1, were RefSeq accession number NP_013943 and Protein Information Resource accession number S45337, respectively.
Construction of Expression Plasmids.
A 2.3-kb SKY1 PCR product was ligated into the low-copy S. cerevisiae expression vector pYCTEF, which consists of the 4.5-kb PvuII backbone fragment from centromeric plasmid YCplac22 (10)
and the 1.0-kb PvuII fragment from p424TEF (11)
, containing the constitutive translation elongation factor 1
promoter. The PCR product was generated using primers SKYex-5 (5'-ATA-GTG-GAT-CCT-GGT-ATA-AAT-AGA-CAC-CCC-C-3') and SKYex-3 (5'-CTA-ACC-TCG-AGA-GGG-CAA-AAT-AAA-GGT-ATA-AAG-G-3'). The full-length human SRPK1 coding region, homologous to SKY1, was kindly provided by Drs. X-D. Fu and H-Y. Wang (University of California at San Diego, La Jolla, CA), and dnSRPK1 (12)
was made available by Drs. X-D. Fu and J-H. Ding (University of California at San Diego). Both constructs were also cloned into the pYCTEF expression vector, enabling heterologous expression in yeast.
Treatment of Cells with Antisense ODNs.
The human ovarian carcinoma A2780 cell line was obtained from the American Type Culture Collection (Manassas, VA), and maintained in HEPES-buffered RPMI 1640 supplemented with 10% fetal bovine serum (Life Technologies, Inc., Rockville, MD) in a humidified incubator at 37°C with 8.5% CO2. Morpholino phosphorodiamidate antisense ODNs directed against the translation initiation site of SRPK1 (referred to henceforth as AS-SRPK1; sequence, 5'-CAT-GGT-GAG-ACC-CAA-CAA-AAG-CAG-G-3'), control random antisense ODNs (referred to henceforth as NS; sequence, 5'-CCT-CTT-ACC-TCA-GTT-ACA-ATT-TAT-A-3'), and control antisense ODNs with four mispairs distributed along the sequence (referred to henceforth as MIS; sequence, 5'-CAT-CGT-GTG-ACC-CAA-CAA-TAG-CTG-G-3'; mismatches are shown in bold) were purchased from Gene Tools (Corvallis, OR). Incubation of A2780 cells with ODNs was performed using the manufacturer’s Special Delivery protocol. Cisplatin sensitivity of ODN-treated A2780 cells was determined by MTT assay (13)
. Briefly, the cells were seeded in 96-well tissue culture plates. The next day, the culture medium was replaced by medium containing ODNs and 0.6 µM ethoxylated polyethylenimine delivery agent but lacking serum, and the cells were incubated at 37°C with 8.5% CO2 for 3 h. Subsequently, the medium was exchanged with standard culture medium containing serum, as described above. After 16 h, cisplatin was added at a dose range of 0–24 µM, and the cells were allowed to grow for another 72 h. Growth inhibition was determined by the use of MTT (Sigma-Aldrich, Zwijndrecht, the Netherlands) as described by Perez et al. (13)
.
Statistical Analysis.
Relationships between cisplatin concentration and cisplatin-induced cytotoxicity were evaluated using Siphar version 4.0 software (InnaPhase, Philadelphia, PA) and the Number Cruncher Statistical System version 5.X package (Dr. J. L. Hintze, University of Utah, East Kaysville, UT). Data were fitted to a sigmoidal maximum effect (Emax) model based on the modified Hill equation, as follows: E = E0 + Emax x [(C
)/(C + EC50)]. In this equation, E0 is the "no drug" effect, Emax is the maximum drug effect, C is the drug concentration to which cytotoxicity is related, EC50 is the drug concentration predicted to result in half-maximal cytotoxicity, and is the Hill constant describing the sigmoidicity of the curve. The difference in EC50 between two cytotoxicity tests was evaluated statistically using a two-tailed (unpaired) Student’s t test.
Immunofluorescence Detection and Western Blot Analysis of SRPK1.
After 3 h of incubation with 5.6 µM ODNs as described above, followed by recovery in standard culture medium, a monolayer of A2780 cells was deposited on slides in a Cytospin 2 Cytocentrifuge (Shandon Inc., Pittsburgh, PA) at 750 rpm for 10 min. Cells were fixed in methanol:acetone (1:1) at -20°C for 10 min, rehydrated in PBS at room temperature for 15 min, and then blocked in blocking buffer (10% rabbit serum, 1% goat serum, and 1% normal human serum in PBS) at room temperature for 15 min. Next, they were incubated at room temperature for 45 min with primary monoclonal anti-SRPK1 (mouse IgG1; 1:50 dilution of the 250 µg/ml stock purchased from BD Transduction Laboratories, Lexington, KY) or nonspecific mouse monoclonal IgG1 (ICN/Cappel, Costa Mesa, CA) at the same final concentration, washed three times with PBS, and developed at room temperature for 30 min with secondary FITC-conjugated goat antimouse IgG (1:50 dilution of the 1 mg/ml stock obtained from Nordic, Tilburg, the Netherlands). Finally, the slides were washed three times in PBS and mounted in VECTASHIELD medium containing 1 µg/ml 4',6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) for examination under a Leica DMR fluorescence microscope with the CGH photoimaging system (Leica Microsystems, Wetzlar, Germany). For Western blotting, A2780 cells were incubated similarly, and total protein was isolated by adding SDS-loading buffer to cell pellets and boiling the samples for 3 min. Western blots were blocked in PBS containing 0.2% Tween 20 and 5% Protifar (Nutricia, Zoetermeer, the Netherlands) at 37°C for 1 h and then incubated with a 1:2000 dilution of mouse monoclonal anti-SRPK1 at 4°C for 16 h. SRPK1 was visualized using horseradish peroxidase-linked goat antimouse IgG (1:4000 dilution of the 400 µg/ml stock purchased from Santa Cruz Biotechnology, Santa Cruz, CA) and SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL). Blots were then stripped in 63 mM Tris (pH 6.8), 0.002% SDS, and 114 mM ß-mercaptoethanol at 56°C for 45 min and reincubated as described above with a 1:5000 dilution of mouse monoclonal anti-ß-actin (Sigma-Aldrich) as first antibody.
|
Results and Discussion |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
35, was introduced into S. cerevisiae cells. Transformation originates from homologous recombination between yeast DNA sequences flanking the transposon and endogenous genomic sequences, leading to replacement of the original genomic copy with the mutagenized version (9)
. A cisplatin-sensitive yeast strain referred to as MGSC131, which displays a steep dose-response curve to the drug (5
, 6)
, was used as recipient. Untransformed MGSC131 cells seeded on cisplatin-containing YNB medium plates did not yield any colonies, even after prolonged incubation. In contrast, when 3 x 105 transformants of library 35 were plated under identical conditions, 31 colonies surviving the one-step drug selection grew within 3–6 days. Upon verification of the resistance phenotypes of the colonies derived from this genome-wide yeast screening approach, we selected nine strains that showed a similar cisplatin resistance level for further characterization. Southern blotting using a transposon-specific probe revealed that each strain contained one single transposon insertion (data not shown). The sites flanking the transposons (i.e., the loci that had been disrupted) could thus be identified directly by means of inverse PCR (8)
, followed by sequencing of the respective products. Sequences of 50–60 bp on either side of the transposon were obtained, and the insertion sites were defined by comparison with public S. cerevisiae databases.
Most prominently, the YMR216C locus corresponding to the SKY1 gene (14)
turned out to be disrupted in at least five transposon-containing cisplatin-resistant yeast strains, referred to as 35-2, 35P-1, 35P-3, 35P-4, and 35P-5. At least three strains (35-2 or 35P-1, 35P-3 or 35P-4, and 35P-5) appeared to contain different insertions in the same gene, as judged by the sizes of the PCR products obtained (Fig. 1a)
. In the remaining transposon-containing cisplatin-resistant yeast strains, other loci had been disrupted, as will be described elsewhere.4
In a quantitative clonogenic survival assay, strains 35-2, 35P-1, 35P-3, 35P-4, and 35P-5 were 4-fold cisplatin resistant as compared with parental MGSC131-SKY1+ cells. Fig. 1b
shows a typical cisplatin sensitivity profile of the transposon-derived sky1 transformant 35-2 as compared with untransformed isogenic SKY1+ cells.
|
, inset), and possible cisplatin resistance of the replacement-derived sky1 mutant (MGSC-sky1) was monitored. Indeed, the cisplatin sensitivity profile appeared to be similar to that of the original transposon-containing sky1 strains (Fig. 1b)
, i.e., MGSC-sky1 cells were 4-fold cisplatin-resistant.
Subsequently, we reintroduced the SKY1 gene into the sky1 deletion mutant cells. For this purpose, the SKY1 open reading frame was cloned into yeast expression vector pYCTEF, and the resulting plasmid was transformed into MGSC-sky1 cells. The transformants became as sensitive to cisplatin as the original MGSC131-SKY1+ strain, whereas transformation with the empty vector alone left the resistance of the MGSC-sky1 cells completely unaffected (Fig. 1b)
. Our findings clearly demonstrate that the cisplatin resistance, which was observed originally, was linked to disruption of the SKY1 gene. Moreover, the data suggest that Sky1p is involved in the cytotoxicity of cisplatin, i.e., that SKY1 might be regarded as a cisplatin sensitivity gene.
Heterologous Expression of the Human Homologue SRPK1 Restores Cisplatin Sensitivity in sky1 Mutant Yeast.
Database analysis revealed that SKY1 has a human homologue, which encodes the SR protein-specific kinase SRPK1. SR protein-specific kinases and the SR proteins that they phosphorylate are thought to be key regulators of RNA processing and, in mammalian cells, alternative splicing through multiple mechanisms (14
, 15)
. The predicted polypeptide sequence encoded by the human SRPK1 cDNA shares 35% identity over 644 amino acids to Sky1p. Notably, SRPK1 and Sky1p also share structural homology: their kinase domains are interrupted by a unique spacer sequence. Because several data suggest strongly that Sky1p and SRPK1 perform homologous functions in vivo (14
, 16)
, we tested SRPK1 for its ability to complement the cisplatin resistance phenotype of S. cerevisiae sky1 cells. SRPK1 was cloned into yeast expression vector pYCTEF and transformed into MGSC-sky1 mutant cells. Heterologous RNA expression was confirmed by Northern blotting (Fig. 2
, inset) using a PCR-generated probe specific for the spacer domain of SRPK1 (14)
. In MGSC-sky1 yeast cells the cisplatin resistance phenotype appeared to be largely reversed by introduction of the human SRPK1 gene, as was the case when the yeast SKY1 gene was reintroduced. In contrast, MGSC-sky1 cells transformed with a construct encoding a well-established dominant-negative kinase-inactive mutant (K109M) of SRPK1 (dnSRPK1; Refs. 12
and 16
) were still cisplatin resistant (Fig. 2)
. Apparently, SRPK1 can functionally substitute SKY1 in S. cerevisiae cells and can therefore be considered a cisplatin sensitivity gene as well. To our knowledge, SKY1 and SRPK1 have not been previously associated with cisplatin sensitivity or resistance. The observation that dnSRPK1 (encoding a kinase-inactive protein) could not substitute SKY1 suggests that the kinase function of SR protein-specific kinases is essential for the cytotoxicity of cisplatin in yeast.
|
, as demonstrated previously (17)
. Treatment of A2780 cells with control antisense ODNs, NS, or MIS had no detectable effect on SRPK1 protein expression levels or subcellular localization (Fig. 3, e–h)
. In contrast, expression of the SRPK1 protein was largely decreased after treatment of A2780 cells with specific AS-SRPK1 (Fig. 3, c and d)
. Incubation with AS-SRPK1 almost completely abolished the nuclear staining of SRPK1 protein (Fig. 3, c and d)
as compared with NS or MIS (Fig. 3, e–h)
, whereas cytoplasmic staining was reduced to the background level detected using a nonspecific antibody (data not shown). Notably, the anti-SRPK1 monoclonal antibody used in these experiments is highly specific: on Western blots, it recognized a single band of 
92 kDa which is in agreement with the relative molecular mass of the SRPK1 protein, as published by Gui et al. (15)
. Furthermore, Western blotting experiments confirmed the specific down-regulation of SRPK1 expression by AS-SRPK1: there was a marked decrease in the level of SRPK1 protein detected on incubation of A2780 cells with AS-SRPK1 as compared with NS or MIS (Fig. 3i)
.
|
, inset). For the ODN dose range tested, the optimum concentration for reduction of cisplatin-induced growth inhibition appeared to be 5.6 µM AS-SRPK1 (Fig. 4
, inset). Subsequently, we determined the shift in EC50 value (i.e., the cisplatin concentration predicted to result in half-maximal cytotoxicity) at a fixed dose of 5.6 µM AS-SRPK1, as compared with the same dose of NS or MIS, by MTT assay. Repeatedly, AS-SRPK1 induced a 3- to 4-fold cisplatin resistance in A2780 cells, as evaluated against incubation with NS or MIS. Notably, the growth rate of A2780 cells in the absence of cisplatin was not decreased after treatment with AS-SRPK1, as compared with NS or MIS (data not shown). A typical experiment (of three performed) is shown in Fig. 4
; whereas incubation with NS, MIS, or delivery agent alone resulted in similar EC50 values (1.5 ± 0.19, 2.2 ± 0.63 and 2.2 ± 0.30 µM cisplatin, respectively), AS-SRPK1 treatment led to a 3- to 4-fold increase in EC50 (6.3 ± 0.70 µM cisplatin). Statistical analysis comparing NS, MIS, or delivery agent only versus AS-SRPK1 treatment indicated that the differences in EC50 were significant at P < 0.0001, as estimated by Student’s t test. It can thus be concluded that down-regulation of SRPK1 protein by specific antisense ODNs rendered A2780 cells resistant to cisplatin, i.e., SRPK1 may function as a cisplatin sensitivity gene in this human ovarian carcinoma cell line.
|
yeast cells, other DNA-damaging agents, including platinum-based drugs, will be used in future studies. Because, in our hands, sky1 strains showed normal growth characteristics,5
and the growth rate of human A2780 cells was not decreased by incubation with specific ODNs, the cisplatin-resistant phenotypes were obviously not caused simply by distorted growth. Because we did not detect altered levels of yeast SKY1 RNA on cisplatin treatment,5
the gene is probably not regulated by cisplatin at the transcriptional level. Sky1p (and SRPK1) activity could be regulated instead by autophosphorylation or posttranslational modification by upstream components. As stated above, our data suggest that the kinase function is essential to the involvement of SR protein-specific kinases in the cytotoxicity of cisplatin. The S. cerevisiae SR protein encoded by NPL3 has been shown (14) to be phosphorylated by Sky1p both in vitro and in vivo and shuttles between the nucleus and the cytoplasm to deliver mRNA and/or proteins. It has been demonstrated (18, 19, 20, 21) that phosphorylation of Npl3p and mammalian SR proteins specifically modulates their protein-protein and protein-RNA interactions and localization. Sky1p and SRPK1 may thus be key players in pathways determining cisplatin sensitivity via mRNA and/or protein delivery by Npl3p or mammalian SR proteins, respectively.
In future studies, we will assess the relative contribution of pathways using SRPK1 to clinical cisplatin sensitivity and resistance. Low levels of cisplatin resistance are generally believed to be sufficient to cause lack of clinical responsiveness. Changes of <2-fold may account for treatment failure in human ovarian carcinoma xenografts (22)
. Interestingly, SRPK1 is highly expressed in testis (23)
, whereas, at the same time, testicular germ cell tumors are extremely sensitive to cisplatin-containing chemotherapy (1)
. Indeed, constitutive expression of SKY1 from a high-copy vector clearly made sky1 yeast cells more sensitive to cisplatin, as compared with an appropriate SKY1+ control strain,5
, 6
which suggests that SR protein-specific kinases are cisplatin sensitivity genes in the sense that they are actively involved in the cytotoxicity of cisplatin. In addition, we found that down-regulation of SRPK1 with AS-SRPK1 also made NT2 testicular cancer cells less sensitive to cisplatin, as compared with cells treated with control MIS.5
Given these observations, we will monitor samples derived from both ovarian and testicular cancers, which are generally treated with cisplatin-containing regimens in the clinic (1)
, for SRPK1 expression and correlation with clinical responsiveness.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported in part by Grant DDHK 97-1397 from the Dutch Cancer Society. 
2 To whom requests for reprints should addressed, at Department of Medical Oncology, University Hospital Rotterdam, Josephine Nefkens Building Room Be422, P. O. Box 1738, 3000 DR Rotterdam, the Netherlands. Phone: 31-10-4088357; Fax: 31-10-4088363; E-mail: nooter{at}oncd.azr.nl
3 The abbreviations used are: EPEI, ethoxylated polyethylenimine, SR, serine/arginine-rich; ODN, oligodeoxynucleotide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; YNB, yeast nitrogen base.
5 P. W. Schenk, K. Nooter, unpublished data.
6 J. A. Brandsma and J. Bronwer, unpublished data.
Received 5/ 4/01. Accepted 8/13/01.
|
REFERENCES |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  R. Lukasiewicz, A. Velazquez-Dones, N. Huynh, J. Hagopian, X.-D. Fu, J. Adams, and G. Ghosh Structurally Unique Yeast and Mammalian Serine-Arginine Protein Kinases Catalyze Evolutionarily Conserved Phosphorylation Reactions J. Biol. Chem., August 10, 2007; 282(32): 23036 - 23043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Hayes, P. E. Carrigan, and L. J. Miller Serine-Arginine Protein Kinase 1 Overexpression Is Associated with Tumorigenic Imbalance in Mitogen-Activated Protein Kinase Pathways in Breast, Colonic, and Pancreatic Carcinomas Cancer Res., March 1, 2007; 67(5): 2072 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Hayes, P. E. Carrigan, A. M. Beck, and L. J. Miller Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res., April 1, 2006; 66(7): 3819 - 3827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-Y. Huang, M. Eddy, M. Vujcic, and D. Kowalski Genome-Wide Screen Identifies Genes Whose Inactivation Confer Resistance to Cisplatin in Saccharomyces cerevisiae Cancer Res., July 1, 2005; 65(13): 5890 - 5897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Wu, J. A. Brown, M. J. Dorie, L. Lazzeroni, and J. M. Brown Genome-Wide Identification of Genes Conferring Resistance to the Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C Cancer Res., June 1, 2004; 64(11): 3940 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Schenk, M. Brok, A. W. M. Boersma, J. A. Brandsma, H. Den Dulk, H. Burger, G. Stoter, J. Brouwer, and K. Nooter Anticancer Drug Resistance Induced by Disruption of the Saccharomyces cerevisiae NPR2 Gene: a Novel Component Involved in Cisplatin- and Doxorubicin-Provoked Cell Kill Mol. Pharmacol., August 1, 2003; 64(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kamachi, T. M. Le, S. J. Kim, M. E. Geiger, P. Anderson, and P. J. Utz Human Autoimmune Sera as Molecular Probes for the Identification of an Autoantigen Kinase Signaling Pathway J. Exp. Med., November 4, 2002; 196(9): 1213 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ishida, J. Lee, D. J. Thiele, and I. Herskowitz From the Cover: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals PNAS, October 29, 2002; 99(22): 14298 - 14302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sanz, L. Mir, and A. Jacquemin-Sablon Bleomycin Resistance in Mammalian Cells Expressing a Genetic Suppressor Element Derived from the SRPK1 Gene Cancer Res., August 1, 2002; 62(15): 4453 - 4458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Schenk, A. W. M. Boersma, M. Brok, H. Burger, G. Stoter, and K. Nooter Inactivation of the Saccharomyces cerevisiae SKY1 Gene Induces a Specific Modification of the Yeast Anticancer Drug Sensitivity Profile Accompanied by a Mutator Phenotype Mol. Pharmacol., March 1, 2002; 61(3): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
), transposon-derived isogenic sky1
), replacement-derived MGSC-sky1
), and MGSC-sky1
) or pYCTEF-SKY1 (•). Percentage survival (colony formation) at each concentration of cisplatin is expressed relative to untreated control cells (100%). Means of three independent experiments performed in triplicate are shown; bars, SD. Bars are sometimes masked by the data point symbols. Northern blotting (inset) using an NH2-terminal SKY1 probe confirmed that whereas MGSC131-SKY1+ cells do express the SKY1 gene (Lane 1), SKY1 mRNA was absent from MGSC-sky1
) or pYCTEF-dnSRPK1 (
